CJC-1295 is a growth-hormone-releasing hormone analog studied for GH support. It is researched most often for Growth hormone release, Body composition and Recovery & sleep. Some human pharmacology studies; not an approved therapy. This guide walks through what CJC-1295 is, how it's studied, what it's commonly combined with, and — just as important — where the science stops. It's educational information only, not medical advice.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is researched for its ability to stimulate the body's own production of growth hormone, and is frequently discussed alongside GH secretagogues.
Also known as: Modified GRF 1-29, DAC:GRF.
How does CJC-1295 work?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release the body's own growth hormone in a more sustained way, and is often researched together with a ghrelin-type secretagogue for a more pulsatile release pattern.
What is CJC-1295 researched for?
In the research and community discussion, CJC-1295 comes up most often in connection with Growth hormone release, Body composition and Recovery & sleep. Remember that "researched for" is not the same as "proven to treat" — these are the directions the science has explored, not established outcomes.
- Growth hormone release
- Body composition
- Recovery & sleep
What does the research actually show?
Some human pharmacology studies; not an approved therapy. The honest framing matters here: promising mechanisms and early results are genuinely interesting, but they are not the same as proven, approved therapy. Anyone presenting CJC-1295 as a guaranteed treatment is getting ahead of the evidence.
What is CJC-1295 typically stacked with?
In the literature and community discussion, CJC-1295 is most often combined with Ipamorelin, based on complementary mechanisms. Selpho never provides dosing or protocols — combinations should only be considered with a licensed professional, since interactions and individual context matter.
Safety and considerations
Affects the endocrine system. Research use only in most regions. Because the responsible framing is educational rather than prescriptive, Selpho provides no dosing, protocols, or purchase links, and always points back to a licensed professional for any decision. If you are dealing with a real health concern, that professional — not a peptide — is where planning should start.
Where to learn more about CJC-1295
To go deeper, see the CJC-1295 library page for a quick reference; published research on PubMed; Selpho's free AI Peptide Advisor to see where CJC-1295 might fit your goals.
Frequently asked questions
Increasing the body's own growth-hormone output, with downstream interest in body composition, recovery, and sleep.
No. Rather than supplying growth hormone directly, it prompts your pituitary to release more of its own. It affects the endocrine system and is research-use in most regions.
It is commonly studied with Ipamorelin. Selpho provides no dosing — endocrine-active compounds should only be considered under medical supervision.
Not sure if CJC-1295 fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis guide is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.